High probability perhaps but not until it is fully functional. I can see a spin off of the diagnostics (Don't forget NuroPro is not to far behind) and then sell where long term investors reap the rewards. I bought IDIX the same time I bought AMBS with the thought of holding a long position on both, I paid 3.50 per share and was bought out for 24.50 per share. Food for thought.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links